Vifor update ASX Announcement for lodgement
Filed with ASX · · 1 page · English
CSL Limited (ASX: CSL; USOTC:CSLLY) has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. CSL now expects the regulatory approval process to take a few more months. CSL remains confident of completing its acquisition of Vifor Pharma AG and looks forward to expanding its presence in the rapidly growing nephrology market, as well as lev
Earlier from CSL
- CSL successfully issues bonds in US debt markets
- Update on Acquisition of Vifor Pharma
- Statutory Accounts for Half Year Ended 31 December 2021
- CSL completes A$750 million Share Purchase Plan
- Successful Completion of A$6.3B Institutional Placement
Later from CSL
- Finalisation of Vifor Pharma Acquisition
- CSL Vifor Market Briefing
- CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
- Appointment of CSLs next CEO & Managing Director
- CSL Half Year Results Announcement & Investor Presentation
Follow CSL into a list and get an email when it puts out news.
Follow CSL